AU2003206148A1 - Nivalenol as specific inhibitor to transcriptional factor c-maf and pharmaceutical compositions comprising the same - Google Patents

Nivalenol as specific inhibitor to transcriptional factor c-maf and pharmaceutical compositions comprising the same

Info

Publication number
AU2003206148A1
AU2003206148A1 AU2003206148A AU2003206148A AU2003206148A1 AU 2003206148 A1 AU2003206148 A1 AU 2003206148A1 AU 2003206148 A AU2003206148 A AU 2003206148A AU 2003206148 A AU2003206148 A AU 2003206148A AU 2003206148 A1 AU2003206148 A1 AU 2003206148A1
Authority
AU
Australia
Prior art keywords
nivalenol
maf
same
pharmaceutical compositions
specific inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003206148A
Other languages
English (en)
Other versions
AU2003206148A8 (en
Inventor
Yoon-Seok Chang
Chung-Yeon Choi
Ju-Hong Jeon
Sang-Hyeon Jo
Heun-Soo Kang
In-Gyu Kim
Yoon-Keun Kim
Kyeong-Eob Min
Sang-Chul Park
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metabolic Engineering Laboratories Co Ltd
Original Assignee
Metabolic Engineering Laboratories Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolic Engineering Laboratories Co Ltd filed Critical Metabolic Engineering Laboratories Co Ltd
Publication of AU2003206148A1 publication Critical patent/AU2003206148A1/en
Publication of AU2003206148A8 publication Critical patent/AU2003206148A8/xx
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003206148A 2002-01-16 2003-01-16 Nivalenol as specific inhibitor to transcriptional factor c-maf and pharmaceutical compositions comprising the same Abandoned AU2003206148A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2002-0002573A KR100485271B1 (ko) 2002-01-16 2002-01-16 전사인자 ｃ－ｍａｆ의 전사 활성 억제제로서의 니발레놀및 그를 포함하는 약제학적 조성물
KR2002/2573 2002-01-16
PCT/KR2003/000099 WO2003059249A2 (en) 2002-01-16 2003-01-16 Nivalenol as specific inhibitor to transcriptional factor c-maf and pharmaceutical compositions comprising the same

Publications (2)

Publication Number Publication Date
AU2003206148A1 true AU2003206148A1 (en) 2003-07-30
AU2003206148A8 AU2003206148A8 (en) 2003-07-30

Family

ID=19718528

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003206148A Abandoned AU2003206148A1 (en) 2002-01-16 2003-01-16 Nivalenol as specific inhibitor to transcriptional factor c-maf and pharmaceutical compositions comprising the same

Country Status (3)

Country Link
KR (1) KR100485271B1 (ko)
AU (1) AU2003206148A1 (ko)
WO (1) WO2003059249A2 (ko)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2626431B1 (en) 2010-10-06 2015-09-16 Fundació Institut de Recerca Biomèdica (IRB Barcelona) Method for the diagnosis, prognosis and treatment of breast cancer metastasis
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
DK2859120T3 (en) 2012-06-06 2019-01-14 Fundacio Inst De Recerca Biomedica Irb Barcelona Method for diagnosis and prognosis of lung cancer metastasis
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
US20140105918A1 (en) 2012-10-12 2014-04-17 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
US20160040247A1 (en) 2013-03-15 2016-02-11 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Method for the diagnosis, prognosis, and tratment of cancer metastasis
WO2017203468A1 (en) 2016-05-25 2017-11-30 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf status
KR20200104298A (ko) 2017-11-22 2020-09-03 인바이오모션 에스.엘. c-MAF 상태에 기반한 유방암의 요법 치료

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118612A (en) * 1987-04-28 1992-06-02 Wisconsin Alumni Research Foundation Assay for trichothecenes
DE3935842A1 (de) * 1989-10-27 1991-05-08 Licentia Gmbh Darstellungsvorrichtung
US5146354A (en) * 1991-05-07 1992-09-08 Compaq Computer Corporation LCD system with a backlight having a light source at a light pipe's edge and with the LCD enframed
KR100603850B1 (ko) * 2000-02-24 2006-07-24 엘지.필립스 엘시디 주식회사 액정표시장치용 배광장치의 도광판 및 시트 고정구조

Also Published As

Publication number Publication date
WO2003059249A3 (en) 2003-11-27
AU2003206148A8 (en) 2003-07-30
WO2003059249A2 (en) 2003-07-24
KR100485271B1 (ko) 2005-04-27
KR20030062137A (ko) 2003-07-23

Similar Documents

Publication Publication Date Title
IL162548A0 (en) 4-Oxoquinoline derivatives and pharmaceutical compositions containing the same
IL166482A0 (en) Dihydropyrazolopyridine derivatives and pharmaceutical compositions containing the same
AU2003263425A1 (en) Dynamic presence indicators
IL166129A0 (en) Pyrrolotriazine derivatives and pharmaceutical compositions containing the same
EP1479666A4 (en) ESTER CONNECTION AND THEIR MEDICAL USE
HUP0105113A3 (en) Benzoheterocycles and their use as mek inhibitors and pharmaceutical compositions containing the compounds
AU2003260345A1 (en) 2-phenylpyridin-4-yl derivatives as alk5 inhibitors
IL157731A0 (en) Caboxylic acid derivatives and pharmaceutical compositions containing the same
AU2003301863A1 (en) SULFONYLAMINOVALEROLAC TAMS AND DERIVATIVES THEREOF AS FACTOR Xa INHIBITORS
IL164455A0 (en) Heterocyclic compounds and pharmaceutical compositions containing the same
AU2003301662A1 (en) Quinazolinones and derivatives thereof as factor xa inhibitors
PL377477A1 (pl) Materiały na bazie żelatyny jako waciki
AU7490900A (en) Chemical compounds and compositions and their use as cathepsin s inhibitors
AU2002246411A1 (en) Inclusion compounds of fumagillol derivative or its salt, and pharmaceutical compositions comprising the same
PL375877A1 (en) Hydantoine derivatives and their use as tace inhibitors
AU2003220361A1 (en) Benzamides and compositions benzamides for use as fungizide
HUP0300318A3 (en) Pyrazolobenzodiazepines as cdk2 inhibitors and pharmaceutical compositions containing them and their use
IL166331A0 (en) 5-arylterazole compounds compositions thereof and uses therefor
AU2003291024A1 (en) Rhodanine derivatives and pharmaceutical compositions containing them
IL164022A0 (en) Phosphate derivatives of fluoroxindole and pharmaceutical compositions containing the same
AU2003259438A1 (en) Di and trifluoro-triazolo-pyridines anti-inflammatory compounds
EP1487776A4 (en) ACID COMPOUNDS AND ESTERS AND METHODS OF USE THEREOF
AU2003210899A1 (en) Adhesive compositions and tapes comprising same
IL174248A0 (en) Alkyl carboxylic acid derivatives and pharmaceutical compositions containing the same
AU2003201071A1 (en) Stable pharmaceutical compositions comprising ace inhibitor(s)

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase